Wednesday 6-25-2014 Pfizer Inc (PFE) $PFE opened a
Post# of 190
Posted On: 06/25/2014 7:37:45 PM
Wednesday 6-25-2014 Pfizer Inc (PFE) $PFE opened at 29.15 hitting the high price of 29.84 and a day low of 29.15 with a total volume of 31,517,974. PFE had a previous close of 29.30 and has been seeing an average volume of 23,192,301.
Overall Average: 24% Sell
Recent stock forum discussions about PFE http://investorshangout.com/search?q=PFE&...mp;yt0=Go!
Most active New York Stock Exchange-traded stocks
AP - 1 hr 27 mins ago
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading: (full story)
Final Glance: Pharmaceuticals companies
AP - 1 hr 27 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)
Should Dividend Investors Eject Pfizer Inc?
David Williamson, The Motley Fool - Motley Fool - 2 hrs 2 mins ago
Pfizer has one of the biggest dividends in health care; but does that make it one of the sector's top dividend stocks? In this video, Motley Fool health-care analyst David Williamson will be grading well-known dividend stocks using a World Cup... (full story)
Midday Glance: Pharmaceuticals companies
AP - Wed Jun 25, 12:36PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.: (full story)
AbbVie cites tax break as a Shire deal motivator
By TOM MURPHY - AP - Wed Jun 25, 11:50AM CDT
U.S. drugmaker AbbVie sees a compelling tax break behind its roughly $46 billion bid to buy British counterpart Shire, and it expects the deal to expand Shire's global reach as well. (full story)
What's the Big Deal With All These Big Deals?
Mark Reeth, Morgan Housel, and Michael Olsen, CFA, The Motley Fool - Motley Fool - Wed Jun 25, 9:54AM CDT
On Tuesday's MarketFoolery , host Mark Reeth, Million Dollar Portfolio analyst Michael Olsen, and Motley Fool One analyst Morgan Housel look at some of the reasons behind the plethora of big deals occurring on the market today. Mark wants to... (full story)
Pain Management Therapeutics Market: Global Industry Analysis, Size, Share, Growth and Forecast 2012 - 2018
PRWeb - Wed Jun 25, 7:20AM CDT
The global pain management therapeutics market is expected to witness a decline during the forecast period (2012 to 2018) due to patent expirations of the key blockbuster revenue generating drugs such as Cymbalta (duloxetine) of Eli Lilly & Co. and Lyrica (pregabalin) of Pfizer, Inc. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics. (full story)
Chronic Back Pain - Pipeline Review, H1 2014
M2 - Wed Jun 25, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c6d5mq/chronic_back_pain) has announced the addition of the "Chronic Back Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Back Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Back Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Back Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Adynxx, Inc. - Akron Molecules GmbH - Astellas Pharma Inc. - Collegium Pharmaceutical, Inc. - Endo Pharmaceuticals Inc. - Grunenthal GmbH - Pfizer Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/c6..._back_pain (full story)
Should Dividend Investors Eject AstraZeneca Stock?
David Williamson, The Motley Fool - Motley Fool - Tue Jun 24, 6:05PM CDT
AstraZeneca (NYSE: AZN) has one of the largest dividends in health care, but does that make it one of the sector's top dividend stocks? In this video, Motley Fool Healthcare analyst David Williamson will be grading well known dividend stocks... (full story)
AstraZeneca Gets a Chance to Prove Its Worth to Pfizer
Brian Orelli, The Motley Fool - Motley Fool - Tue Jun 24, 1:09PM CDT
A company that rejects a buyout proposal with a 45% stock-price premium had better deliver on its case for being worth more than the offer. AstraZeneca gets an early shot to prove its worth tomorrow when a Food and Drug Administration's... (full story)
Why TheStreet Ratings Team Rates Pfizer (PFE) Stock a "Buy"
at The Street - Tue Jun 24, 12:52PM CDT
TheStreet Ratings team reiterates its "buy" rating on Pfizer (PFE) with a ratings score of B+. (full story)
Walgreen 3Q profit jumps but misses expectations
By TOM MURPHY - AP - Tue Jun 24, 11:10AM CDT
Walgreen's fiscal third quarter earnings jumped 16 percent compared with last year, aided in part by a lower income tax rate, but the drugstore chain's performance again fell short of Wall Street's expectations. (full story)
Early Glance: Pharmaceuticals companies
AP - Tue Jun 24, 9:52AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)
Pfizer Invites Public to View and Listen to Webcast of July 29 Conference Call with Analysts
Business Wire - Tue Jun 24, 9:00AM CDT
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 29, 2014. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2014 Performance Report, to be issued that morning. (full story)
Global Choroidal Neovascularization (CNV) Market 2014-2018 with Bayer, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
M2 - Tue Jun 24, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbmxjk/global_choroidal) has announced the addition of the "Global Choroidal Neovascularization (CNV) Market 2014-2018" report to their offering. The current competition in the Global CNV market is strong as the available treatment options and marketed products have been successful in meeting the market requirement, while treating the underlying cause of the disease. The current market drugs include Lucentis, approved for CNV associated with wet AMD; Macugen, approved for CNV associated with wet AMD; and Visudyne, approved for CNV associated with wet AMD, presumed ocular histoplasmosis, and pathologic myopia. Apart from these, Avastin, which is currently used as an off-label drug has gradually captured a major share of the market. In addition, the CNV pipeline seems to be promising with various molecules in the development phase. These products are expected to meet the unmet needs in the market and will provide physicians with a wider choice in treating CNV. The Global CNV market is driven by several factors, of which high patient and physician satisfaction is one of the major drivers. High patient and physician satisfaction has resulted in increased demand for CNV treatment therapies. Further, the report states that one of the major challenges is the high cost of treatment. Many patients do not have the required budget for investing in high cost treatment options. Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. Other Prominent Vendors - Affitech A/S - Allergan Inc. - Chengdu Kanghong Biotech Co. Ltd. - Gilead Sciences Inc. - Lpath Inc. - Mat Biopharma SAS - Pfizer Inc. - Promedior Inc. - QLT Inc. - Quark Pharmaceuticals Inc. - Resolvyx Pharmaceuticals Inc. - Sanwa Kagaku Kenkyusho Co. Ltd. - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Product Portfolio of Current CNV Therapies - Clinical Pipeline Portpolio - Rate of Incidence and Prevalence - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/vb..._choroidal (full story)
Overall Average: 24% Sell
Recent stock forum discussions about PFE http://investorshangout.com/search?q=PFE&...mp;yt0=Go!
Most active New York Stock Exchange-traded stocks
AP - 1 hr 27 mins ago
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading: (full story)
Final Glance: Pharmaceuticals companies
AP - 1 hr 27 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)
Should Dividend Investors Eject Pfizer Inc?
David Williamson, The Motley Fool - Motley Fool - 2 hrs 2 mins ago
Pfizer has one of the biggest dividends in health care; but does that make it one of the sector's top dividend stocks? In this video, Motley Fool health-care analyst David Williamson will be grading well-known dividend stocks using a World Cup... (full story)
Midday Glance: Pharmaceuticals companies
AP - Wed Jun 25, 12:36PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.: (full story)
AbbVie cites tax break as a Shire deal motivator
By TOM MURPHY - AP - Wed Jun 25, 11:50AM CDT
U.S. drugmaker AbbVie sees a compelling tax break behind its roughly $46 billion bid to buy British counterpart Shire, and it expects the deal to expand Shire's global reach as well. (full story)
What's the Big Deal With All These Big Deals?
Mark Reeth, Morgan Housel, and Michael Olsen, CFA, The Motley Fool - Motley Fool - Wed Jun 25, 9:54AM CDT
On Tuesday's MarketFoolery , host Mark Reeth, Million Dollar Portfolio analyst Michael Olsen, and Motley Fool One analyst Morgan Housel look at some of the reasons behind the plethora of big deals occurring on the market today. Mark wants to... (full story)
Pain Management Therapeutics Market: Global Industry Analysis, Size, Share, Growth and Forecast 2012 - 2018
PRWeb - Wed Jun 25, 7:20AM CDT
The global pain management therapeutics market is expected to witness a decline during the forecast period (2012 to 2018) due to patent expirations of the key blockbuster revenue generating drugs such as Cymbalta (duloxetine) of Eli Lilly & Co. and Lyrica (pregabalin) of Pfizer, Inc. This report studies the global market for pain management therapeutics from three perspectives - therapeutic classes of drugs, indications and geography. Each of these segments is further classified into sub-segments; therapeutic classes include anticonvulsants, antidepressants, anesthetics, NSAIDs, opioids, anti-migraine agents and other non-narcotic analgesics. (full story)
Chronic Back Pain - Pipeline Review, H1 2014
M2 - Wed Jun 25, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c6d5mq/chronic_back_pain) has announced the addition of the "Chronic Back Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Back Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Back Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Back Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Adynxx, Inc. - Akron Molecules GmbH - Astellas Pharma Inc. - Collegium Pharmaceutical, Inc. - Endo Pharmaceuticals Inc. - Grunenthal GmbH - Pfizer Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/c6..._back_pain (full story)
Should Dividend Investors Eject AstraZeneca Stock?
David Williamson, The Motley Fool - Motley Fool - Tue Jun 24, 6:05PM CDT
AstraZeneca (NYSE: AZN) has one of the largest dividends in health care, but does that make it one of the sector's top dividend stocks? In this video, Motley Fool Healthcare analyst David Williamson will be grading well known dividend stocks... (full story)
AstraZeneca Gets a Chance to Prove Its Worth to Pfizer
Brian Orelli, The Motley Fool - Motley Fool - Tue Jun 24, 1:09PM CDT
A company that rejects a buyout proposal with a 45% stock-price premium had better deliver on its case for being worth more than the offer. AstraZeneca gets an early shot to prove its worth tomorrow when a Food and Drug Administration's... (full story)
Why TheStreet Ratings Team Rates Pfizer (PFE) Stock a "Buy"
at The Street - Tue Jun 24, 12:52PM CDT
TheStreet Ratings team reiterates its "buy" rating on Pfizer (PFE) with a ratings score of B+. (full story)
Walgreen 3Q profit jumps but misses expectations
By TOM MURPHY - AP - Tue Jun 24, 11:10AM CDT
Walgreen's fiscal third quarter earnings jumped 16 percent compared with last year, aided in part by a lower income tax rate, but the drugstore chain's performance again fell short of Wall Street's expectations. (full story)
Early Glance: Pharmaceuticals companies
AP - Tue Jun 24, 9:52AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)
Pfizer Invites Public to View and Listen to Webcast of July 29 Conference Call with Analysts
Business Wire - Tue Jun 24, 9:00AM CDT
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 29, 2014. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2014 Performance Report, to be issued that morning. (full story)
Global Choroidal Neovascularization (CNV) Market 2014-2018 with Bayer, F. Hoffmann-La Roche, Novartis & Regeneron Pharmaceuticals Dominating
M2 - Tue Jun 24, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vbmxjk/global_choroidal) has announced the addition of the "Global Choroidal Neovascularization (CNV) Market 2014-2018" report to their offering. The current competition in the Global CNV market is strong as the available treatment options and marketed products have been successful in meeting the market requirement, while treating the underlying cause of the disease. The current market drugs include Lucentis, approved for CNV associated with wet AMD; Macugen, approved for CNV associated with wet AMD; and Visudyne, approved for CNV associated with wet AMD, presumed ocular histoplasmosis, and pathologic myopia. Apart from these, Avastin, which is currently used as an off-label drug has gradually captured a major share of the market. In addition, the CNV pipeline seems to be promising with various molecules in the development phase. These products are expected to meet the unmet needs in the market and will provide physicians with a wider choice in treating CNV. The Global CNV market is driven by several factors, of which high patient and physician satisfaction is one of the major drivers. High patient and physician satisfaction has resulted in increased demand for CNV treatment therapies. Further, the report states that one of the major challenges is the high cost of treatment. Many patients do not have the required budget for investing in high cost treatment options. Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. Other Prominent Vendors - Affitech A/S - Allergan Inc. - Chengdu Kanghong Biotech Co. Ltd. - Gilead Sciences Inc. - Lpath Inc. - Mat Biopharma SAS - Pfizer Inc. - Promedior Inc. - QLT Inc. - Quark Pharmaceuticals Inc. - Resolvyx Pharmaceuticals Inc. - Sanwa Kagaku Kenkyusho Co. Ltd. - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Product Portfolio of Current CNV Therapies - Clinical Pipeline Portpolio - Rate of Incidence and Prevalence - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/vb..._choroidal (full story)
(0)
(0)Pfizer Inc. (PFE) Stock Research Links
Scroll down for more posts ▼